Literature DB >> 24396137

Tissue penetration of antifungal agents.

Timothy Felton1, Peter F Troke, William W Hope.   

Abstract

Understanding the tissue penetration of systemically administered antifungal agents is critical for a proper appreciation of their antifungal efficacy in animals and humans. Both the time course of an antifungal drug and its absolute concentrations within tissues may differ significantly from those observed in the bloodstream. In addition, tissue concentrations must also be interpreted within the context of the pathogenesis of the various invasive fungal infections, which differ significantly. There are major technical obstacles to the estimation of concentrations of antifungal agents in various tissue subcompartments, yet these agents, even those within the same class, may exhibit markedly different tissue distributions. This review explores these issues and provides a summary of tissue concentrations of 11 currently licensed systemic antifungal agents. It also explores the therapeutic implications of their distribution at various sites of infection.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24396137      PMCID： PMC3910906          DOI： 10.1128/CMR.00046-13

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN： 0893-8512            Impact factor:   26.132


  253 in total

1.  Penetration of oral fluconazole into gynecological tissues.

Authors:  H Mikamo; K Kawazoe; Y Sato; K Izumi; T Ito; K Ito; T Tamaya
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 2.  Protein binding: do we ever learn?

Authors:  Markus A Zeitlinger; Hartmut Derendorf; Johan W Mouton; Otto Cars; William A Craig; David Andes; Ursula Theuretzbacher
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 3.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Authors:  Jodi M Lestner; Susan J Howard; Joanne Goodwin; Lea Gregson; Jayesh Majithiya; Thomas J Walsh; Gerard M Jensen; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

5.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

6.  Population pharmacokinetics of voriconazole in adults.

Authors:  William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

7.  Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

Authors:  Karl V Clemons; Julie A Schwartz; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

8.  Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation.

Authors:  Fiona O Zwald; Margaret Spratt; Bianca D Lemos; Emir Veledar; Clint Lawrence; George Marshall Lyon; Suephy C Chen
Journal:  Dermatol Surg       Date:  2012-05-02       Impact factor: 3.398

9.  Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole.

Authors:  P De Doncker; J Decroix; G E Piérard; D Roelant; R Woestenborghs; P Jacqmin; F Odds; A Heremans; P Dockx; D Roseeuw
Journal:  Arch Dermatol       Date:  1996-01

10.  Pharmacokinetics of amphotericin B and flucytosine.

Authors:  A Polak
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401
View more
  113 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 2.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model.

Authors:  M Ghannoum; N Isham; D Angulo; K Borroto-Esoda; S Barat; L Long
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis.

Authors:  François Barde; Eliane Billaud; Lauriane Goldwirt; Catherine Horodyckid; Vincent Jullien; Fanny Lanternier; Philippe Lesprit; Lucie Limousin; Jérémie F Cohen; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

5.  Identification of the environmental source of infection for a domestic ferret with cryptococcosis.

Authors:  Laura J Schmertmann; Alison Wardman; Laura Setyo; Alex Kan; Wieland Meyer; Richard Malik; Mark B Krockenberger
Journal:  J Vet Diagn Invest       Date:  2019-09-24       Impact factor: 1.279

Review 6.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

7.  Muscle diffusion of liposomal amphotericin B and posaconazole in critically ill burn patients receiving continuous hemodialysis.

Authors:  Quentin Ressaire; Christophe Padoin; Marc Chaouat; Veronique Maurel; Alexandre Alanio; Axelle Ferry; Sabri Soussi; Mourad Benyamina; Blandine Denis; Maurice Mimoun; Alexandre Mebazaa; Matthieu Legrand
Journal:  Intensive Care Med       Date:  2015-03-24       Impact factor: 17.440

Review 8.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

9.  Emydomyces testavorans, a New Genus and Species of Onygenalean Fungus Isolated from Shell Lesions of Freshwater Aquatic Turtles.

Authors:  Daniel B Woodburn; Andrew N Miller; Matthew C Allender; Carol W Maddox; Karen A Terio
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

10.  The Added Value of Longitudinal Imaging for Preclinical In Vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis.

Authors:  Greetje Vande Velde; Uwe Himmelreich; Liesbeth Vanherp; Jennifer Poelmans; Amy Hillen; Guilhem Janbon; Matthias Brock; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.